

Full Portfolio Holdings* as of August 31, 2023

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
BASE CURRENCY					
US DOLLAR			6,312,145	6,312,145	0.53%
COMMON STOCKS					
Eli Lilly & Co.			178,763	99,070,455	8.26%
UnitedHealth Group, Inc.			178,246	84,948,479	7.09%
Merck & Co., Inc.			624,266	68,032,509	5.68%
Danaher Corp.			203,565	53,944,725	4.50%
Pfizer, Inc.			1,413,620	50,013,876	4.17%
Zoetis, Inc.			174,331	33,211,799	2.77%
Humana, Inc.			67,394	31,111,092	2.60%
Thermo Fisher Scientific, Inc.			54,880	30,573,648	2.55%
Stryker Corp.			107,087	30,364,519	2.53%
Boston Scientific Corp.			558,609	30,131,369	2.51%
HCA Healthcare, Inc.			98,652	27,356,200	2.28%
Vertex Pharmaceuticals, Inc.			73,727	25,682,063	2.14%
Centene Corp.			405,497	24,998,890	2.09%
AstraZeneca plc			346,187	23,478,402	1.96%
Edwards Lifesciences Corp.			272,030	20,802,134	1.74%
Molina Healthcare, Inc.			66,228	20,538,627	1.71%
Abbott Laboratories			198,234	20,398,279	1.70%
Cencora, Inc.			115,506	20,326,746	1.70%
Agilent Technologies, Inc.			142,113	17,205,621	1.44%
DexCom, Inc.			167,430	16,907,081	1.41%
ICON plc			63,750	16,571,175	1.38%
Daiichi Sankyo Co. Ltd.			529,825	15,605,282	1.30%
Illumina, Inc.			83,071	13,724,991	1.14%
United Therapeutics Corp.			60,055	13,473,940	1.12%
Regeneron Pharmaceuticals, Inc.			15,651	12,935,395	1.08%
Biogen, Inc.			46,634	12,468,066	1.04%
Laboratory Corp. of America Holdings			57,553	11,976,779	1.00%
Becton Dickinson & Co.			42,538	11,887,244	0.99%
UCB SA			131,834	11,825,120	0.99%
Eisai Co. Ltd.			184,295	11,650,426	0.97%
Encompass Health Corp.			159,016	11,296,497	0.94%
Acadia Healthcare Co., Inc.			141,823	10,934,553	0.91%
Insulet Corp.			54,890	10,522,962	0.88%
Bristol-Myers Squibb Co.			168,590	10,393,574	0.87%
Hologic, Inc.			136,463	10,199,245	0.85%
Chugai Pharmaceutical Co. Ltd.			332,400	10,132,185	0.85%
Novartis AG			89,985	9,056,244	0.76%
Waters Corp.			28,236	7,928,669	0.66%
Cytokinetics, Inc.			223,019	7,792,284	0.65%
Surgery Partners, Inc.			209,796	7,607,203	0.63%

Full Portfolio Holdings* as of August 31, 2023

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Repligen Corp.			43,500	7,565,085	0.63%
Exact Sciences Corp.			87,975	7,360,868	0.61%
Argenx SE			14,609	7,340,876	0.61%
Shockwave Medical, Inc.			32,944	7,260,528	0.61%
agilon health, Inc.			394,172	6,984,728	0.58%
Alkermes plc			232,127	6,775,787	0.57%
GSK plc			380,203	6,659,610	0.56%
Privia Health Group, Inc.			248,232	6,516,090	0.54%
Elanco Animal Health, Inc.			515,753	6,292,187	0.52%
Addus HomeCare Corp.			71,217	6,245,731	0.52%
Karuna Therapeutics, Inc.			32,611	6,123,041	0.51%
Teleflex, Inc.			28,172	5,993,311	0.50%
Abcam plc			258,773	5,853,445	0.49%
Inari Medical, Inc.			87,182	5,808,065	0.48%
Alnylam Pharmaceuticals, Inc.			28,551	5,647,959	0.47%
DiaSorin SpA			50,509	5,333,584	0.44%
Gilead Sciences, Inc.			68,853	5,265,877	0.44%
Genmab AS			13,712	5,253,549	0.44%
Ascendis Pharma AS			51,923	5,089,492	0.42%
Tecan Group AG			12,039	4,800,180	0.40%
Avantor, Inc.			219,395	4,749,902	0.40%
Bio-Techne Corp.			60,463	4,740,299	0.40%
Veracyte, Inc.			175,604	4,635,946	0.39%
Seagen, Inc.			20,617	4,248,545	0.35%
Verona Pharma plc			217,778	4,231,427	0.35%
Moderna, Inc.			36,738	4,153,966	0.35%
Immunocore Holdings plc			70,364	3,959,382	0.33%
Genus plc			127,537	3,751,994	0.31%
Zai Lab Ltd.			145,114	3,696,054	0.31%
Sarepta Therapeutics, Inc.			27,489	3,326,444	0.28%
QuidelOrtho Corp.			40,106	3,303,130	0.28%
PTC Therapeutics, Inc.			81,674	3,226,123	0.27%
Revolution Medicines, Inc.			92,941	3,157,206	0.26%
ImmunoGen, Inc.			196,691	3,115,585	0.26%
Merus NV			139,158	3,112,964	0.26%
Vaxcyte, Inc.			59,715	3,100,403	0.26%
Celldex Therapeutics, Inc.			109,594	3,057,673	0.26%
Otsuka Holdings Co. Ltd.			79,300	3,012,743	0.25%
Sage Therapeutics, Inc.			141,109	2,822,180	0.24%
Owens & Minor, Inc.			165,785	2,801,767	0.23%
Morphic Holding, Inc.			49,710	2,738,027	0.23%
Apellis Pharmaceuticals, Inc.			64,600	2,726,766	0.23%
Hapvida Participacoes e Investimentos SA			3,016,575	2,595,008	0.22%
Guardant Health, Inc.			64,991	2,539,848	0.21%
Inspire Medical Systems, Inc.			10,530	2,389,046	0.20%

Full Portfolio Holdings* as of August 31, 2023

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.			239,000	2,331,380	0.19%
Syndax Pharmaceuticals, Inc.			120,695	2,234,064	0.19%
Blueprint Medicines Corp.			40,776	2,033,091	0.17%
Ultragenyx Pharmaceutical, Inc.			46,630	1,715,518	0.14%
Prothena Corp. plc			30,357	1,603,457	0.13%
Aclaris Therapeutics, Inc.			213,429	1,596,449	0.13%
Smith & Nephew plc			66,921	903,100	0.08%
Ono Pharmaceutical Co. Ltd.			16,445	310,678	0.03%
Contra Abiomed, Inc.			7,416	7,564	0.00%
FOREIGN CURRENCY					
BRAZILIAN REAL			1,906,284	384,949	0.03%
EURO CURRENCY			117	127	0.00%
DANISH KRONE			447	65	0.00%
SWISS FRANC			12	14	0.00%
HONG KONG DOLLAR			37	5	0.00%
JAPANESE YEN			1	0.01	0.00%
REPURCHASE AGREEMENTS					
FIXED, Inc. CLEARING CORP.REPO		9/1/2023	1,610,611	1,610,611	0.13%
DERIVATIVES - FOREIGN CURRENCY EXCHANGE CONTRACTS (SPOT)					
EURO CURRENCY		9/1/2023	(105,749)	851	0.00%
SWISS FRANC		9/1/2023	(54,897)	379	0.00%
POUND STERLING		9/1/2023	(60,789)	288	0.00%
SWISS FRANC		9/1/2023	(28,522)	193	0.00%
DANISH KRONE		9/5/2023	(249,059)	16	0.00%
JAPANESE YEN		9/5/2023	(3,592,918)	(53)	0.00%
TOTAL INVESTMENTS				1,187,485,656	99.06%
OTHER ASSETS LESS LIABILITIES				11,304,665	0.94%
TOTAL NET ASSETS				1,198,790,320	100.00%

* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on www.hartfordfunds.com for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual report to shareholders filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

227833 03/22